脑转移瘤再程放疗的前瞻性II期试验:放射外科治疗
这项前瞻性II期试验纳入全脑放疗后复发的脑转移瘤患者,采用更严格的选择标准(KPS≥70、NFS 0-1、病灶直径≤20 mm)行放射外科再程放疗,SRS剂量不超过20 Gy。59例患者共109个病灶,完全和部分缓解率42%,2年控制率81%,中位总生存14个月,未观察到放射性坏死。
要点
- 严格选择KPS≥70、NFS 0-1、病灶≤20 mm的患者行SRS再程放疗。
- SRS剂量不超过20 Gy,中位剂量18 Gy,未发生放射性坏死。
- 完全和部分缓解率42%,2年控制率81%,中位OS 14个月。
核心结论
- 更严格的患者选择(KPS≥70、NFS 0-1、脑转移灶直径≤20 mm)和SRS剂量≤20 Gy可获得高总生存率、持续>2年的完全和部分缓解,且无脑放射性坏死。
研究设计与样本
- 前瞻性II期试验,纳入全脑放疗后复发的脑转移瘤患者行SRS再程放疗。
- 共59例患者、109个脑转移灶,病灶直径范围6-20 mm。
- 从既往WBRT到SRS的中位间隔为15个月,SRS中位剂量18 Gy(范围10-20 Gy)。
主要发现
- 完全和部分缓解(CR、PR)在42%的患者中取得,2年控制率为81%。
- 再程放疗后中位总生存(OS)为14个月。
- 未检测到放射性坏死。
关键数值与推荐
- 入组标准:KPS≥70、神经功能评分(NFS)0-1、病灶直径≤20 mm。
- SRS剂量从未超过20 Gy。
- 与既往发表的试验相比,本次更严格的选择和剂量限制使放射性坏死从6%降至0%。
临床怎么用
- 对WBRT后复发的脑转移瘤患者,可考虑SRS再程放疗,但应严格筛选KPS≥70、NFS 0-1且病灶直径≤20 mm者。
- SRS剂量应控制在≤20 Gy,以限制放射性坏死风险。
局限性
- 原文未报告
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: In our previous published trial on radiosurgery (SRS) of recurrent brain metastases (BM) after whole brain radiotherapy (WBRT), Karnofsky performance status (KPS) and administered dose conditioned outcome and late toxicity, respectively. Brain radionecrosis was registered in 6% of patients. With the aim to obtain similar satisfactory outcomes and limit toxicity, we started a phase II trial in which reirradiation of BM with SRS were done using a tighter patient selection. MATERIALS AND METHODS: Patients with BM recurring after WBRT were recruited for reirradiation with SRS. Only patients with good KPS (≥70), good neurologic functional score (NFS 0-1) and lesions with a diameter ≤20 mm were considered eligible for retreatment. Dose exceeding 20 Gy was never administered. RESULTS: The 59 patients reirradiated had 109 BM with a diameter range of 6-20 mm. Median interval between prior WBRT and SRS was 15 months and median SRS administered dose was 18 Gy (range 10-20 Gy). Complete and partial response (CR, PR) was obtained in 42% of patients with 2 years of control rate of 81%. Median overall survival (OS) after reirradiation was 14 months. No radionecrosis was detected. CONCLUSIONS: Analysis of our current trial compared with results of our previous data suggests that a tighter patient selection (KPS ≥ 70; NFS 0-1, BM with ≤20 mm of diameter) and SRS dose ≤20 Gy allowed a high OS rate, a good percentage of CR and PR which last for >2 years, and no brain radionecrosis.
引用
- Maranzano E, Terenzi S, Anselmo P, et al. A prospective phase II trial on reirradiation of brain metastases with radiosurgery. Clin Transl Radiat Oncol. 2019. PMID: 31061900. doi:10.1016/j.ctro.2019.04.003
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。